Source comparison
CJC-1295 No DAC Safety Studies: Evidence Comparison
Teichman et al. 2006 49 participants 28 days 100 mcg/kg Injection-site erythema (18%) None reported Resting HR/BP only None Largest trial; short observation window limits chronic safety signal detection Ionescu & Frohman 2006 18 participants 7 days 30 mcg/kg M
This comparison does not assign a generated winner or score.
- Teichman et al. 2006
- 49 participants
- 28 days
- 100 mcg/kg
- Injection-site erythema (18%)
- None reported
- Resting HR/BP only
- None
- Largest trial; short observation window limits chronic safety signal detection
- Ionescu & Frohman 2006
- 18 participants
- 7 days
- 30 mcg/kg
- Mild injection-site reaction (17%)
- Proof-of-concept GH pulsatility study; no extended monitoring
- Alba et al. 2006
- 24 participants
- 14 days
- 60 mcg/kg
- Transient flushing (4%)
- Only trial assessing metabolic markers; findings limited by brief duration
- CJC-1295 DAC (discontinued)
- 47 participants
- Up to 90 days
- Injection-site nodules, fibrosis
- Cardiovascular events in 2 participants
- ECG, echocardiography
- Trial halted
- DAC formulation abandoned due to safety signals; serves as cautionary reference